Wegovy (semaglutide) could offer a new option to treat severe liver disease based on new clinical trial evidence. The GLP-1 ...

The FDA accepted Novo Nordisk's NDA for an oral formulation of Wegovy. The agency is expected to release its verdict on the ...

Hims & Hers Health Inc. posted better-than-expected first-quarter revenue as the company pivots away from making copycat ...

Hims & Hers Health reports strong Q1 results with 111% revenue growth, 38% subscriber growth, and sets 2030 targets. Read ...

That controversial Super Bowl ad appears to have paid off for Hims & Hers as the company's first-quarter revenue doubled year ...

The game is afoot in the obesity space as GLP-1 rivals Eli Lilly and Novo Nordisk take their showdown to a new level. Lilly ...

Weight loss medications and bariatric surgery used to be considered last-resort options, but now, they’re everywhere. More ...

NAUSEA, constipation, breathing problems, racing heart… the list of Ozempic side effects appears to be growing by the day.

Hims & Hers shares fell in extended trading on Monday after the company reported first-quarter earnings that offered soft ...

This time next year, you may be swapping your GLP-1 injections for easier and as-effective oral weight-loss medication. It's ...

AbbVie snagged yet another spot among April’s highest TV ad spenders, as its Vraylar jumped two spots to eighth place with a ...

Hims & Hers Health first-quarter revenue more than doubled as subscribers rose 38%, while its second-quarter sales outlook ...